Skip to Content
You are currently on the new version of our website. Access the old version .
  • Review
  • Open Access

1 November 2019

18 Pages

Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers

,
,
,
,
,
,
,
,
…
1
Department of Medicine and Surgery, Pathology, San Gerardo Hospital, University of Milano- Bicocca, 20900 Monza, Italy
2
Division of Pathology, IEO-European Institute of Oncology IRCCS, 20141 Milan, Italy
3
Department of Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy
4
Department of Pathology, University Hospital of Cologne, Institute of Pathology, 50924 Cologne, Germany
This article belongs to the Special Issue Cancer Immunoediting and Beyond

Abstract

Immunotherapy has become the standard-of-care in many solid tumors. Despite the significant recent achievements in the diagnosis and treatment of cancer, several issues related to patients’ selection for immunotherapy remain unsolved. Multiple lines of evidence suggest that, in this setting, the vision of a single biomarker is somewhat naïve and imprecise, given that immunotherapy does not follow the rules that we have experienced in the past for targeted therapies. On the other hand, additional immune-related biomarkers that are reliable in real-life clinical practice remain to be identified. Recently, the immune-checkpoint blockade has been approved in the US irrespective of the tumor site of origin. Further histology-agnostic approvals, coupled with with tumor-specific companion diagnostics and guidelines, are expected in this field. In addition, immune-related biomarkers can also have a significant prognostic value. In this review, we provide an overview of the role of these biomarkers and their characterization in the management of lung cancer, melanoma, colorectal cancer, gastric cancer, head and neck cancer, renal cell carcinoma, urothelial cancers, and breast cancer.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.